Article

When to consider corneal cross-linking treatment

Author(s):

Julianne Mobilian
Conferences|ASCRS

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment 

Audrey Talley Rostov, MD, discusses corneal cross-linking (CXL) complications, and when to consider CXL treatment at the 2019 annual ASCRS meeting in San Diego.

RELATED: Intense pulsed light therapy for the treatment of chalazia

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
Fasika Woreta, MD, MPH, Eugene de Juan, M.D. Professor of Ophthalmic Education at Wilmer Eye Institute’s Baltimore and Columbia locations, discusses the NMA meeting
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
Related Content
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain
March 31st 2025

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Alcon acquires majority interest in Aurion Biotech
March 27th 2025

Alcon acquires majority interest in Aurion Biotech

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
March 20th 2025

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial

Bausch + Lomb announces launch of new intelligent Arise lens fitting system
March 18th 2025

Bausch + Lomb announces launch of new intelligent Arise lens fitting system

© 2025 MJH Life Sciences

All rights reserved.